Influence of antiviral therapy on the dynamics of blood endothelin-1, asymmetrical dimethylarginine and von Willebrand factor levels in patients with chronic hepatitis C

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Evaluation of the effect of antiviral therapy (AVT) on the dynamics of blood endothelin 1 (Et-1), asymmetric dimethylarginine (ADMA) and von Willebrand factor (VWF) levels in patients with chronic hepatitis C (CHC).

Materials and methods. A total of 107 patients with chronic HCV infection (77 with CHC and 30 with Child–Pugh class A liver cirrhosis) were examined. All patients received narlaprevir in combination with Peg-IFN-α2a and ribavirin for 24 weeks. Blood Et-1, ADMA level and VWF activity were determined.

Results. Patients with chronic HCV infection showed a significant increase in the mean Et-1 and ADMA blood levels. Increased VWF activity was recorded exclusively at the stage of liver cirrhosis. After the 4th week of AVT, the Et-1 level decreased by 47% from the initial level, the ADMA concentration decreased by 41%.

Conclusion. In patients with chronic HCV infection, signs of endothelial dysfunction were detected, as evidenced by an increase in the blood Et-1 and ADMA levels. AVT using narlaprevir in combination with Peg-IFN-α2a and ribavirin helps to normalize the functional state of the endothelium.

Full Text

Restricted Access

About the authors

Irina P. Grushko

Rostov Research Institute of Microbiology and Parasitology

Author for correspondence.
Email: gip75@rambler.ru
ORCID iD: 0000-0003-1133-667X

Infectiologist, Junior Researcher at the Laboratory of Sanitary and Parasitological Monitoring, Medical Parasitology and Immunology

Russian Federation, Rostov-оn-Don

Elena B. Romanova

Rostov Research Institute of Microbiology and Parasitology

Email: eromanova1961@yandex.ru
ORCID iD: 0000-0002-6885-6126

MD, Associate Professor, Chief Researcher at the Laboratory of Sanitary and Parasitological Monitoring, Medical Parasitology and Immunology

Russian Federation, Rostov-оn-Don

Tatiana I. Tverdokhlebova

Rostov Research Institute of Microbiology and Parasitology; Rostov State Medical University

Email: rostovniimp@mail.ru
ORCID iD: 0000-0002-3912-0291

MD, Director; Professor at the Department of Epidemiology

Russian Federation, Rostov-оn-Don; Rostov-оn-Don

References

  1. ВОЗ. Гепатит С: информационный бюллетень [Электронный ресурс]. 24.06.2022. https://www.who.int/ru/news-room/fact-sheets/detail/ hepatitis-c. World Health Organization. Hepatitis C: information bulletin [Electronic resource] – 24.06.2022. https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c
  2. Mascolini M. Global status update on the HCV prevalence and cascade of care entering 2020 – lack of progress – presented at AASLD. November 12–15, 2021, https://natap.org/2021/AASLD/AASLD_40.htm
  3. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения Российской Федерации в 2022 году». https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=25076. State report «On the state of sanitary and epidemiological welfare of the population of the Russian Federation in 2022».. https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=25076
  4. Ющук Н.Д., Знойко О.О., Якушечкина Н.А., Дудина К.Р., Шутько С.А., Козина А.Н. и др. Оценка социально-экономического бремени гепатита С в Российской Федерации. Эпидемиология и Вакцинопрофилактика 2013; 2(69): 18‒33. Yuschuk N.D., Znoyko O.O., Yakushechkina N.A., Dudina K.R., Shut’ko S.A., Kozina A.N. et al. Assessment of the Socio-Economic Burden of Hepatitis C in the Russian Federation. Epidemiology and Vaccinal Prevention. 2013; 2(69): 18‒33. (In Russ.).
  5. Никитин И.Г., Попович Л.Д., Потапчик Е.Г. Экономическое бремя хронического гепатита C в России. Эпидемиол. инфекц. болезни. Актуал. вопр. 2015; (6): 9–13. Nikitin I.G., Popovich L.D., Potapchik E.G. The economic burden of chronic hepatitis C in Russia. Epidemiоlоgy and infectious diseases. Сurrent items 2015; 6: 9–13. (In Russ.).
  6. Морозова Т.С. Роль эндотелиальной дисфункции в развитии хронических диффузных заболеваний печени (обзор литературы). Уральский медицинский журнал 2016; 8(141): 145–152. Morozova T.S. The role of endothelial dysfunction in the development of chronic diffuse liver diseases (literature review). Ural Medical Journal 2016; 8(141): 145–152. (In Russ.).
  7. Мельникова Ю.С., Макарова Т.П. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней. Казанский медицинский журнал 2015; 4(96): 659–665. doi: 10.17750/KMJ2015-659. Mel’nikova Yu.S., Makarova T.P. Endothelial dysfunction as the key link of chronic diseases pathogenesis. Kazan Medical Journal. 2015; 4(96): 659–665. (In Russ.). doi: 10.17750/KMJ2015-659
  8. Liuch P., Segarra G., Medina P. Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. World J. Gastroenterol. 2015; 21(32): 9466–9475. doi: 10.3748/wjg.v21.i32.9466
  9. Szlachcic A., Krzysiek-Maczka G., Pajdo R., Targosz A. The impact of asymmetric dimethylarginine (ADMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage. Curr. Pharm. Des. 2013; 19(1): 90–97. doi: 10.2174/13816128130113.
  10. Антонова Т.В., Романова М.А., Лымарь Ю.В. Маркеры активации эндотелия (VCAM-1, vWF) при хроническом гепатите С. Терапевтический архив 2013; 85(12): 86–89. Antonova T.V., Romanova M.A., Lymar Yu.V. Markers of endothelial activation (VCAM-1, vWF) in chronic hepatitis C. Therapeutic archive 2013; 85(12): 86–89. (In Russ.).
  11. Чистякова М.В., Говорин А.В., Радаева Е.В. Функциональное состояние эндотелия у пациентов с вирусным гепатитом и циррозом печени. Казанский медицинский журнал 2014; 95(1): 41–45. Chistyakova M.V., Govorin A.V., Radaeva E.V. The functional state of the endothelium in patients with viral hepatitis and liver cirrhosis. Kazan Medical Journal 2014; 95(1): 41–45. (In Russ.).
  12. Щекотова А.П. Клинико-лабораторные показатели и эндотелиальная дисфункция при заболеваниях печени, их диагностическая, прогностическая значимость и возможности использования для оценки эффективности терапии. Клинические перспективы гастроэнтерологии, гепатологии 2015; (5): 50–51. Schyokotova A.P. Clinical and laboratory parameters and endothelial dysfunction at liver – diseases, their diagnostic, prognostic value and potential of application for treatment response rate rating. Clinical prospects of gastroenterology, hepatology 2015; (5): 50–51. (In Russ.).
  13. Герасимов А.А. Последние достижения в коррекции функционального состояния эндотелия. Современные проблемы науки и образования 2015; (3). https://science-education.ru/ru/article/view?id=19398. Gerasimov A.A. Recent achievements in the correction of the functional state of the endothelium. Modern Problems of Science and Education 2015; (3). (In Russ.). https://science-education.ru/ru/article/view?id=19398
  14. Филиппов Е.В. Возможности коррекции эндотелиальной дисфункции у пациентов с артериальной гипертензией и ишемической болезнью сердца. Медицинский совет 2019; (5): 64–67. doi: 10.21518/2079-701X-2019-5-64-67. Filippov E.V. Possibilities for correcting endothelial dysfunction. Medical Council 2019; (5): 64–67. (In Russ.). doi: 10.21518/2079-701X-2019-5-64-67
  15. Елагина А.А., Ляшев Ю.Д., Артюшкова Е.Б., Ляшев А.Ю., Проняева Т.В., Абдул Рахман Шехине. Коррекция пептидными препаратами эндотелиальной дисфункции при сахарном диабете. Экспериментальная и клиническая фармакология 2020; 83(11): 12–15. doi: 10.30906/0869-2092-2020-83-11-12-15. Elagina A.A., Lyashev Yu.D., Artyushkova E.B., Lyashev A. Yu., Pronyaeva T.V., Abdul Rahman Chahine. Peptide preparations protect endothelium against dysfunction caused by diabetes mellitus. Experimental and clinical pharmacology 2020; 83(11): 12–15. (In Russ.). doi: 10.30906/0869-2092-2020-83-11-12-15
  16. Корой П.В. Влияние противовирусной терапии на функциональные показатели эндотелия при HCV-ассоциированной патологии печени. Медицинский вестник Северного Кавказа 2009; (2): 43‒48. Koroy P.V. Influence of antiviral therapy on the functional endothelial parameters in the chronic liver diseases, associated with HCV. Medical News of the North Caucasus 2009; (2): 43‒48. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Mean Et-1 (a) and ADMA (6) levels in patients with CHC depending on the stage of fibrosis

Download (92KB)
Indexing metadata
3. Fig. 2. Mean indices of vWF activity in patients with chronic HCV infection

Download (73KB)
Indexing metadata
4. Fig. 3. Dynamics of Еt-1 (a) and ADMA (b) levels in patients with CHC depending on the response to AVT

Download (134KB)
Indexing metadata

Copyright (c) 2025 Bionika Media